SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor is drawing attention ahead of the FDAs November 22 target decision on deramiocel for Duchenne muscular dystrophy, with traders weighing whether the amended application and longer-term upper-limb data could support approval. Bullish speculation has been reinforced by commercial-launch job postings and optimism about FDA flexibility, while skeptics cite prior advisory-panel concerns and caution that hiring does not guarantee approval; INOs separate FDA approval has also provided a sentiment tailwind.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 636,822,022.65079832 with 590,150,211.79771733 in circulation. The last known price of Solana is 94.05303263 USD and is down -1.56 over the last 24 hours. It is currently trading on 1189 active market(s) with $1,556,044,818.54 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solana is drawing attention amid a broad crypto pullback, with traders debating whether concerns over Binances reported security incident and exchange trust are adding pressure or coinciding with an existing market downtrend. Sentiment is split between bearish calls for further weakness and buyers treating the decline as an opportunity to accumulate and stake.

Cardano (ADA) is a cryptocurrency launched in 2017. Cardano has a current supply of 44,994,665,205.855202 with 36,823,860,963.224877 in circulation. The last known price of Cardano is 0.19280151 USD and is up 0.00 over the last 24 hours. It is currently trading on 1752 active market(s) with $154,401,668.14 traded over the last 24 hours. More information can be found at https://www.cardano.org.

Cardano

ADAs volatile price action and technical levels dominate the discussion, with traders debating whether rebounds and breakout setups can hold or whether further weakness will follow. Sentiment is sharply divided between dip-buying and short-squeeze hopes on one side, and concerns about continued losses and a lack of altcoin momentum on the other.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs record October deliveries, including sharply higher overseas sales, are driving discussion, but traders are debating whether volume growth can translate into better margins and meet the companys Q4 delivery ambitions. The upbeat operating update is being weighed against a steep share-price decline and concerns about China EV competition and profitability.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,809.831273 with 281,866,746.118905 in circulation. The last known price of OFFICIAL TRUMP is 1.73532194 USD and is up 9.97 over the last 24 hours. It is currently trading on 744 active market(s) with $259,407,006.57 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

A modest rebound has prompted pump and short-squeeze chatter around the Trump-themed meme coin, while most discussion focuses on its steep decline and accusations that it is a speculative pump-and-dump. Some holders remain bullish, but skeptics warn of further losses.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is drawing attention after a sharp selloff alongside AI and optical peers, with traders pointing to broader risk-off sentiment and concerns about dilution, valuation, and execution rather than a clear company-specific setback. Bulls are buying the dip on data-center optics demand and upcoming earnings, while skeptics remain wary of further declines.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to a 52-week high ahead of the Q3 report is driving attention, with bullish traders pointing to BRIUMVIs commercial growth and speculating about a short squeeze or buyout. Others caution that the buyout talk is unconfirmed and that the earnings results and upcoming subcutaneous BRIUMVI data will be important tests of the rally.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Positioning around Luckins scheduled third-quarter earnings report is the main focus, with traders hoping for strong results and a rally while others expect a post-report pullback. The debate is amplified by frustration over the stocks prolonged weak, range-bound trading and speculation about buybacks or a future relisting.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons quarterly earnings beat and strong refining results are driving attention, with traders highlighting higher shareholder returns and record-high shares. The reaction is broadly positive, though some caution that the stock looks extended and refining strength may not last if margins normalize.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gileads strong third-quarter results and raised outlook, led by continued HIV drug demand, are driving attention as shares reach fresh highs. Traders are broadly upbeat about the earnings and breakout, though some remain cautious after the run-up.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oversold Conditions For Dyne Therapeutics (DYN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes

Equity

RBC Capital highlighted differences in how Novartis’ and Dyne’s drugs target transferrin protein, their payloads, and their clinical trial designs.

NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy

The company said on Tuesday that its experimental drug del-desiran failed in a late-stage trial. 

Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling

Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.read more...

SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?

Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.

Dyne Therapeutics Stock Tumbles After Hours: Here's Why

Dyne Therapeutics stock fell after hours after pricing an upsized $375M public offering of common stock.read more...

Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock

Dyne Therapeutics announced plans to raise $300 million through a public stock offering on Tuesday.


SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space

Citi reiterated a ‘Sell’ rating on SRPT, citing the expected rise in competition within the Duchenne muscular dystrophy (DMD) exon-skipping market.


DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?

Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program strengthen confidence in its pipeline.

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026...

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Dyne Therapeutics Inc

Neutral Sentiment

<ul class="summary-bullets"><li>RBC Capital cut its target to $30 from $35 while keeping an ‘Outperform’ rating, according to The Fly.</li><li>Dyne is developing Z-Basivarsen for myotonic dystrophy type 1.</li><li>On Tuesday, Novartis said its Phase 3 study of Del-Desiran failed to achieve its primary goal in patients with myotonic dystrophy type 1.</li></ul>Shares of Dyne Therapeutics (DYN) extended their sell-off on Wednesday, as Wall Street weighed the risk to its experimental muscle-disease drug following a major Phase 3 setback for Novartis (NVS).At the time of writing, <a href="https://stocktwits.com/symbol/DYN">DYN shares</a> traded 4.2% lower, having crashed more than 16% in the previous session.<h2 class="st-heading-2">Why DYN Stock Tanked</h2>On Tuesday, Novartis <a href="http://stocktwits.com/news-articles/markets/equity/nvs-stock-on-track-for-worst-day-in-over-20-years-after-second-trial-failure-in-a-week-dyn-srpt-slip-in-sympathy/cZtEeAyRJy2">said</a> its Phase 3 study of Del-Desiran failed to achieve its primary goal in patients with myotonic dystrophy type 1 (DM1). The rare genetic disease causes progressive muscle weakness and difficulty relaxing muscles after contraction, and currently has no approved treatment.Dyne is developing Z-Basivarsen for the same disease. Both companies’ studies use video hand opening time (vHOT), which measures how quickly a patient can open their hand after making a tight fist.Novartis’ drug failed to produce a statistically significant improvement on that measure, with Baird raising concerns about whether Dyne could face a similar problem.Dyne has enrolled 71 patients in the registrational expansion portion of its Phase 1/2 Achieve study for Z-Basivarsen. Topline results are expected in the first quarter of 2027.<h2 class="st-heading-2">Wall Street Remains Bullish</h2>Following Novartis’ trial data, Baird lowered its price target on Dyne to $26 from $30 but maintained an ‘Outperform’ rating, saying Novartis’ failure creates a challenging read-through for Dyne. The updated target still represents about 37% upside from current levels.RBC Capital also cut its target to $30 from $35 while keeping an ‘Outperform’ rating, but cautioned against directly applying Novartis’ results to Dyne. The firm pointed to differences in how the drugs target transferrin, their payloads, and their clinical trial designs, which it believes could lead to different outcomes.Morgan Stanley also said Novartis’ failure raises risk but believes Dyne's program still has potential. The brokerage lowered the target to $36 from $45 and maintained an ‘Overweight’ rating.The stock has a 12-month consensus price target of $37.53, while 16 of the 17 analysts covering the stock have rated it a ‘Buy’ and one ‘Sell,’ according to Koyfin.<h2 class="st-heading-2">Retail Says Go Long On DYN</h2>Despite the slump, retail sentiment surrounding DYN on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.One user saw the slide in share price as a “long opportunity.”<stembedurl>https://stocktwits.com/CC_Abbott/message/663855724</stembedurl>DYN shares have gained around 5.5% so far in 2026.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/cmps-stock-defies-market-selloff-after-compass-pathways-psilocybin-trial-success-pointing-to-2027-launch/cZt7EeeRJzj">CMPS Stock Defies Market Selloff After Compass Pathways Psilocybin Trial Success Pointing To 2027 Launch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of US biotech company Dyne Therapeutics Inc. is displayed on a smartphone in front of abstract background on computer screen. (Photo Illustration by Timon Schneider/SOPA Images/LightRocket via Getty Images)

Novartis AG

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$16.69
Prev Close	$17.04
Open	$16.97
Dividend Yield	0.00%
50-Day Moving Average	$18.53
Beta	1.95
Avg. Volume	3.62M
PE Ratio	-5.01

52-Week High	$27.31
52-Week Low	$14.00
Market Capitalization	$3.12B
EPS (Annual)	-$3.47
Price to Book	3.94
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

DYN Fundamentals